Company intelligence / Profile preview

BioCircuit Technologies

Atlanta, Georgia, United States

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Nerve Tape, the company's flagship product, received FDA 510(k) clearance and is the first FDA-cleared sutureless device for nerve repair. Over 3,500 devices have been implanted in approximately 16 months of commercialization as of August 2025.

Therapeutic areas: Neurology
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

National Institutes of Health (NIH)Global Nerve FoundationSmithfield BioScience

Beyond the preview

Go deeper on BioCircuit Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioCircuit Technologies.

Explore the full profile